Efficacy
tumour
DISEASE PROGRESSION, DISEASE, TUMOUR, BEST
In cohort A1, efficacy data was evaluable for 11 patients, with two showing partial response, six showing stable disease and three showing disease progression at 12 weeks quantified by RECIST 1.1 (Fig. Best overall response for cohorts A1 and A2 by patient treatment schedule. All response categories were determined according to RECIST 1.1 criteria.Progression-free survival times for all patients, including censoring and tumour type annotations.Figure Patient case: 3 axial CT slices at radiotherapy planning, 3 months of treatment w/ berzosertib, 10-month follow-up.In cohort A2, efficacy data was evaluable for eight patients, with three showing radiographic partial response, four displaying stable disease, and one displaying disease progression quantified by RECIST 1.1 at 12 weeks (Fig. 